Merck & Co., Inc.

The transcript provided on page 7 and adjacent pages does not mention any current or planned fundraising activities through debt or equity by Merck. Key points relevant to funding and investment include: - Focus on strategic business development and acquisitions, particularly of mid- to late-stage assets. - Strong commercial momentum and robust cash flow generation. - No explicit discussion or indication of raising funds through new debt or equity offerings. - Emphasis on internal R&D and commercial execution to drive growth. Thus, based on the transcript, there is no disclosed current or future plan for fundraising via debt or equity at this time.

- Merck remains committed to investing appropriately to realize the promise of its expansive early- and late-phase pipeline and support promotion of key growth drivers. - The company will prioritize investments in the business to drive near- and long-term growth. - Continued investment in the innovative pipeline, including the initiation of multiple clinical trials across novel candidates with potential to address unmet medical needs. - Commitment to dividends and using business development to add compelling science to the pipeline remains a priority. - Merck has ample capacity given its strong investment-grade credit rating and cash flow to pursue value-enhancing, bolt-on acquisitions. - Strategic investments focus on leveraging cutting-edge science to improve patient lives and deliver sustainable innovation. - Plans include advancing clinical programs in vaccines, oncology, HIV, and pulmonary arterial hypertension with ongoing launches and regulatory submissions.

- Merck expects full-year 2024 revenues between $63.8 billion and $64.3 billion, reflecting 5%-7% year-over-year growth despite foreign exchange headwinds. - Strong growth driven by KEYTRUDA demand and expanding vaccines portfolio, including GARDASIL and VAXNEUVANCE. - GARDASIL growth to continue, supported by planned new multivalent HPV vaccine offering broader protection and ongoing global vaccination efforts. - KEYTRUDA's subcutaneous formulation launch anticipated in 2025 aims to increase patient access and expand market share, especially in combination therapies and earlier-stage cancers. - Wind River launch for pulmonary arterial hypertension expected to add new revenue streams with high commercial interest. - Business development remains a priority to sustain growth through mid- to later-stage assets. - Long-term outlook confident, with multiple growth drivers and sustainable innovation pipeline targeting continued expansion through 2030 and beyond.

- Merck raised and narrowed its 2024 full-year revenue guidance to $63.6 billion - $64.3 billion, reflecting 5%-7% growth year-over-year including FX impacts. - Earnings Per Share (EPS) guidance increased and narrowed to a range of $8.53 to $8.65 for 2024, despite $0.05 negative impact from foreign exchange. - Gross margin expected to be approximately 81%. - Operating expenses estimated between $25.2 billion and $26.1 billion, with potential business development costs included. - Company emphasizes strategic investments in innovative pipeline and business development to drive long-term growth. - Confident in near- and long-term outlook fueled by strong demand for key products like KEYTRUDA and GARDASIL. - Leadership expects sustainable growth drivers through 2028 and beyond, with a staggered loss of exclusivity (LOE) schedule easing impact. - Confident in delivering value through innovation, operational excellence, and expanding commercial capabilities.

The provided transcript sections from Merck's Q1 2024 earnings call do not explicitly mention current or expected orderbook details or pending orders. However, relevant insights include: - Strong momentum and robust demand across Merck’s portfolio, indicating healthy ongoing sales. - Specific mention of the Wind River launch focused on securing coverage and access, with programs ensuring patient access. - GARDASIL sales showed growth with significant manufacturing scaling planned for 2025 to meet demand. - Ongoing efforts to drive growth in vaccines and oncology, with several late-stage candidates approaching approval. - Commercial execution is emphasized as strong, with strategic business development supporting pipeline expansion. - No explicit numerical data on orderbooks or pending orders is provided in the transcript. Thus, while growth and launch momentum suggest a strong order pipeline, detailed current or expected orderbook figures are not disclosed.